Updated:
OrbiMed Advisors
OrbiMed manages ~$20B across venture, public equity, and credit — investing from seed-stage biotech to large public healthcare companies globally.
OrbiMed Advisors
OrbiMed Advisors is an SEC-registered investment adviser in New York, NY, registered since 2002. The firm manages $20.6 billion in assets. It has 118 employees and 86 investment advisers.
General information
Firm type
Generalist
Year founded
—
AUM
~$20B (per the firm)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
San Francisco, CA · Shanghai, China · Herzliya, Israel · Hong Kong · London, UK
Sector focus
Frequently asked questions
How is OrbiMed structured across its investment strategies?
OrbiMed operates three core strategies: private equity, public equity, and private credit/royalty. The private equity arm invests from seed-stage venture through growth equity, typically as a lead investor. The public equity strategy runs long/short event-driven funds and closed-end investment trusts. The credit/royalty arm provides non-dilutive structured debt to commercial-stage healthcare companies and monetizes royalty streams for IP holders.
Does OrbiMed invest only in private companies, or does it also hold public positions?
OrbiMed invests across the full lifecycle. Its private equity funds back early-stage and growth companies, while separate public-equity funds take long and short positions in publicly traded healthcare companies worldwide. This means a private portfolio company that goes public could remain a holding within the public funds.
What geographies does OrbiMed cover?
OrbiMed invests globally with offices in New York, San Francisco, Shanghai, Herzliya, Hong Kong, and London. Its portfolio includes companies headquartered in North America, Asia, and Europe, and it has committed over $2 billion specifically to developing-country healthcare infrastructure.
What sets OrbiMed's model apart from a pure venture capital firm in healthcare?
OrbiMed combines venture capital with public equity hedge funds and a structured credit/royalty business — all under one healthcare mandate. This allows the firm to provide equity early, non-dilutive debt later, and maintain public-market exposure post-IPO, which is uncommon among dedicated life-sciences VCs.
How large is OrbiMed's team, and what expertise does it bring?
The firm employs over 150 professionals, including scientists, medical experts, and investment staff. This multidisciplinary team supports due diligence across biopharma, medical devices, diagnostics, healthcare IT, and services globally.
Does OrbiMed participate in fund commitments or only direct deals?
OrbiMed executes primarily direct investments across its private equity and credit strategies. The firm is typically a lead investor in its venture and growth deals. It does not publicly market itself as a fund-of-funds, though its public-equity vehicles invest in publicly traded healthcare securities.
How active is OrbiMed in company creation versus backing existing start-ups?
OrbiMed has backed over 110 life sciences start-ups and its venture portfolio companies have brought over 80 new therapies to patients. The firm engages in both company creation and investment in established private companies, often taking an active role in building management teams and strategic direction.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: